Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...
Opens in a new tab or window The FDA has approved osimertinib (Tagrisso ... 21 L858R mutations as detected by an FDA-approved test. Approval was based on data from the LAURA trial, the results ...
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.
